Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide.
• Current treatments like chemoradiotherapy, targeted therapy, and immunotherapy have improved survival but have limitations.
• Novel therapeutic strategies with reduced toxicity are urgently needed for effective NSCLC treatment.

Purpose of the Study:

• To review the anti-NSCLC mechanisms of curcumin (Cur) and its analogs.
• To explore the potential of Cur and its analogs as standalone or combination therapies for NSCLC.
• To analyze the clinical trial data for Cur in NSCLC treatment.

Main Methods:

• Systematic literature review of anti-NSCLC mechanisms of Cur and its analogs using the PubMed database.
• In silico analysis of Cur's interaction with NSCLC molecular targets using Discovery Studio.
• Compilation and analysis of available clinical trial data for Cur in NSCLC treatment.

Main Results:

• Curcumin exhibits anticancer effects against NSCLC through various mechanisms.
• Clinical trial results for Cur in NSCLC have been inconsistent, indicating challenges in application.
• Cur analogs and combination therapies involving Cur show potential for enhanced efficacy.

Conclusions:

• Curcumin and its analogs demonstrate potential as therapeutic agents or adjuvants in lung cancer treatment.
• Further investigation into optimizing Cur-based therapies and combination strategies is warranted.
• Addressing the challenges in clinical application is crucial for realizing the full therapeutic potential of Cur in NSCLC.